Inactivated Mycoplasma hyopneumoniae strain J Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

inactivated mycoplasma hyopneumoniae strain j

intervet australia pty limited - inactivated mycoplasma hyopneumoniae strain j - unknown - inactivated mycoplasma hyopneumoniae strain j vaccine - general active 0.0 - immunotherapy

M+PAC MYCOPLASMA HYOPNEUMONIAE INACTIVATED VACCINE FOR PIGS Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

m+pac mycoplasma hyopneumoniae inactivated vaccine for pigs

intervet australia pty limited - mycoplasma hyopneumoniae strain j; thiomersal - misc. vaccines or anti sera - mycoplasma hyopneumoniae strain j vaccine-general active 1.0 rp; thiomersal mercury other 0.01 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

Suvaxyn Circo+MH RTU European Union - English - EMA (European Medicines Agency)

suvaxyn circo+mh rtu

zoetis belgium sa - inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2 orf2 protein, inactivated mycoplasma hyopneumoniae, strain p-5722-3 - inactivated viral and inactivated bacterial vaccines - pigs - for active immunisation of pigs from 3 weeks of age against porcine circovirus type 2 (pcv2) to reduce viral load in blood and lymphoid tissues and fecal shedding caused by infection with pcv2.for active immunisation of pigs over the age of 3 weeks against mycoplasma hyopneumoniae to reduce lung lesions caused by infection with m. hyopneumoniae.

RESPISURE ONE MYCOPLASMA HYOPNEUMONIAE VACCINE Australia - English - APVMA (Australian Pesticides and Veterinary Medicines Authority)

respisure one mycoplasma hyopneumoniae vaccine

zoetis australia pty ltd - mycoplasma hyopneumoniae - inactivated antigen; thiomersal - misc. vaccines or anti sera - mycoplasma hyopneumoniae - inactivated antigen vaccine-general active 31600.0 ru/2ml; thiomersal mercury other 0.1 mg/ml - immunotherapy - pigs | boar | gilt | piglet | sow | swine - mycoplasma hyopneumoniae | pneumonia | bacterial pneumonia | reduction of lung lesions | respiratory disease | swine enzootic pneumonia

PORCILIS M HYO, SUSPENSION FOR INJECTION Ireland - English - HPRA (Health Products Regulatory Authority)

porcilis m hyo, suspension for injection

intervet ireland limited - mycoplasma hyopneumoniae strain 11 inactivated whole cell concentrate - suspension for injection - unknown - mycoplasma vaccine - porcine - immunological - inactivated vaccine

Porcilis M Hyo, suspension for injection Ireland - English - HPRA (Health Products Regulatory Authority)

porcilis m hyo, suspension for injection

intervet ireland limited - mycoplasma hyopneumoniae strain 11 inactivated whole cell concentrate - suspension for injection - . - mycoplasma - pigs - immunological - inactivated vaccine

Mhyosphere PCV ID European Union - English - EMA (European Medicines Agency)

mhyosphere pcv id

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - pigs - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies).to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies.to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies).mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

STELLAMUNE MYCOPLASMA Ireland - English - HPRA (Health Products Regulatory Authority)

stellamune mycoplasma

elanco gmbh - inactivated mycoplasma hyopneumoniae (strain p-5722-3) - emulsion for injection - . - mycoplasma

Suvaxyn M.hyo - Parasuis, suspension for injection for pigs Ireland - English - HPRA (Health Products Regulatory Authority)

suvaxyn m.hyo - parasuis, suspension for injection for pigs

zoetis belgium s.a. - inactivated mycoplasma hyopneumoniae (strain p-5722-3); inactivated haemophilus parasuis serovar 4, strain 2170b; inactivated haemophilus parasuis serovar 5, strain ia84-29755 - suspension for injection - . - mycoplasma + haemophilus - pigs - immunological - inactivated vaccine

CircoMax Myco European Union - English - EMA (European Medicines Agency)

circomax myco

zoetis belgium - inactivated mycoplasma hyopneumoniae, strain p-5722-3, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2a open reading frame 2 (orf2) protein, inactivated recombinant chimeric porcine circovirus type 1 containing the porcine circovirus type 2b orf2 protein - immunologicals for suidae - pigs (for fattening) - active immunisation of pigs against porcine circovirus type 2 to reduce viral load in blood and lymphoid tissues, fecal shedding and the lesions in lymphoid tissues associated with pcv2 infection. protection was demonstrated against porcine circovirus types 2a, 2b and 2d.active immunisation of pigs against mycoplasma hyopneumoniae to reduce the lung lesions associated with mycoplasma hyopneumoniae infection. onset of immunity (both vaccination schedules): 3 weeks after (the last) vaccination. duration of immunity (both vaccination schedules): 23 weeks after (the last) vaccination. in addition, vaccination has been shown to reduce body weight gain losses under field conditions.